AVDL News and Press, Avadel Pharmaceuticals plc From 04/26/22

What To Know About Buying Penny Stocks on April 26th With so many penny stocks to choose from, it can seem difficult to pick the best ones to buy. However, because there is such a large variety of small caps out there, finding ones that have the opportunity to be profitable, is complete...

The shares of clinical-stage pharma Avadel Pharmaceuticals (NASDAQ:AVDL) have added ~35% in the pre-market Tuesday even as the company moved to address concerns over its recent trading volatility. On Monday, Avadel (AVDL) reported interim data for its lead product candidate is FT218...

Jiuzi Holdings (JZXN) +88% enters into an equity acquisition agreement to acquire automobile sales serviceshop operator under top China automaker Geely Auto's premium electronic vehicle brand geometry. Avadel Pharmaceuticals (AVDL) +35% provides comment on Recent trading activity. Gamida...

DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a statement in response to the trading volatility and subsequent brief trading halt of its shares t...

Gainers: Avadel Pharmaceuticals  (AVDL) +31%. AlloVir (ALVR) +7%. Redbox Entertainment  (RDBX) +6%. CymaBay Therapeutics  (CBAY) +5%. Harpoon Therapeutics. (HARP) +5%. Losers: Protagonist Therapeutics (PTGX) -41%. Nkarta (NKTX) -6%. Provention Bio (PRVB...

Results from patient preference questionnaire indicate that people with narcolepsy preferred the once-nightly over the twice-nightly dosing regimen for oxybates Nocturnal adverse event questionnaires characterize the burden associated with the second dose required for tw...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) traded at a new 52-week high today of $15.50. This new high was reached on above average trading volume as 38.6 million shares traded hands, while the average 30-day volume is approximately 378,000 shares. Over the past year, Avadel Pharmaceutical...

Avadel Pharmaceuticals (NASDAQ:AVDL) announced the publication of positive secondary goal data from a phase 3 trial of FT218 to treat excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. The results were published in CNS Drugs. The company had previously report...

Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared to placebo in adults with narcolepsy New data bolster positive primary endpoint data from the completed Phase 3 REST-ON trial and indicate that FT218 posit...

We are initiating AVDL at a speculative buy rating, with a target price of USD 14. We like AVDL's lead candidate FT218, and we believe the upcoming PDUFA on March 31st to be the critical catalyst for the company. We believe AVDL will be able to generate USD ~300M peak sales. ...